Trial · NCT00297258

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

NCT00297258, Phase 2, Completed, GlaxoSmithKline; results first posted 2010-01-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma. Trials, record NCT00297258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00297258

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
NCT number: NCT00297258
Status: Completed
Phases: Phase 2
Enrollment: 148 participants, actual
Lead sponsor: GlaxoSmithKline
Conditions: Sarcoma, Soft Tissue
Interventions: pazopanib
First posted: 2006-02-28
Last updated: 2016-02-03
Results first posted: 2010-01-06

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival at Week 12	Week 12	Progression free survival at week 12 is the number of participants who had a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) or stable disease (SD, no change) 12 weeks from start of therapy, per response evaluation criteria in solid tumors (RECIST v1.0). Clinical progression is progression of disease without documented radiological evidence. Progressive disease (PD), a \>=20% increase in target lesions.
Secondary	Overall Survival	Start of therapy until death (up to approximately 5 years)	Overall survival is defined as the time from start of therapy until death. Participants who were still alive at the time of analysis were censored.
Secondary	Progression Free Survival	Start of therapy until progression (up to approximately 5 years)	Progression free survival is defined as the interval between the start of treatment and the earliest date of disease progression or death due to any cause. Assessments of progression were made by the investigator.
Secondary	Overall Response	Baseline until either response or progression (up to approximately 5 years)	Overall response is the number of participants who had a best outcome of a complete response (CR, all detectable tumor had disappeared) or a partial response (PR, a \>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum) per response evaluation criteria in solid tumors (RECIST v1.0) at some point during the study. Progressive disease (PD), a \>=20% increase in target lesions. Clinical progression is progression of disease without documented radiological evidence.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival at Week 12	Week 12	Intent-to-Treat (ITT) Population: All eligible participants entered into the study and who had taken \>=1 dose of investigational product. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.	participants	NUMBER
SECONDARY	Overall Survival	Start of therapy until death (up to approximately 5 years)	ITT Population. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.	years	MEDIAN
SECONDARY	Progression Free Survival	Start of therapy until progression (up to approximately 5 years)	Intent-to-Treat (ITT) Population: all eligible participants who had started therapy. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.	years	MEDIAN
SECONDARY	Overall Response	Baseline until either response or progression (up to approximately 5 years)	Intent-to-Treat (ITT) Population: all eligible participants who had started therapy. Four participants were considered not evaluable for efficacy by the study coordinator for one of the following reasons: absence of target lesions, documented progression at trial entry, or ineligible histology.	participants	NUMBER

Source ClinicalTrials.gov

Results by group60

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Progression Free Survival at Week 12	Pazopanib 800 mg - Adipocytic Tumors	Complete Response	0	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Leiomyosarcoma	Complete Response	0	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Synovial Sarcoma	Complete Response	0	participants
Progression Free Survival at Week 12	Pazopanib 800mg - Other Soft Tissue Sarcoma (STS)	Complete Response	0	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Adipocytic Tumors	Partial Response	0	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Leiomyosarcoma	Partial Response	1	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Synovial Sarcoma	Partial Response	4	participants
Progression Free Survival at Week 12	Pazopanib 800mg - Other Soft Tissue Sarcoma (STS)	Partial Response	1	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Adipocytic Tumors	Stable Disease	5	participants
Progression Free Survival at Week 12	Pazopanib 800 mg - Leiomyosarcoma	Stable Disease	16	participants

1 to 10 of 60Source ClinicalTrials.gov

See all 60 results by group

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pazopanib 800 mg	142
Overall Study	COMPLETED	Pazopanib 800 mg	0
Overall Study	NOT COMPLETED	Pazopanib 800 mg	142

Source ClinicalTrials.gov

Adverse events76

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Fatigue	General disorders	Pazopanib 800 mg	84	142
other	Diarrhoea	Gastrointestinal disorders	Pazopanib 800 mg	62	142
other	Nausea	Gastrointestinal disorders	Pazopanib 800 mg	60	142
other	Hypertension	Vascular disorders	Pazopanib 800 mg	57	142
other	Skin hypopigmentation	Skin and subcutaneous tissue disorders	Pazopanib 800 mg	53	142
other	Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Pazopanib 800 mg	51	142
other	Vomiting	Gastrointestinal disorders	Pazopanib 800 mg	48	142
other	Decreased appetite	Metabolism and nutrition disorders	Pazopanib 800 mg	45	142
other	Weight decreased	Metabolism and nutrition disorders	Pazopanib 800 mg	45	142
other	Constipation	Gastrointestinal disorders	Pazopanib 800 mg	33	142

1 to 10 of 76Source ClinicalTrials.gov

See all 76 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pazopanib 800 mg
Total, other adverse events	Pazopanib 800 mg	137	142
Total, serious adverse events	Pazopanib 800 mg	39	142

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
19451427	BACKGROUND	PubMed
22805326	BACKGROUND	PubMed
24504442	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00297258

GET https://conductscience.org/api/trials/v1/NCT00297258/results?page=2

API reference For AI assistants